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Less efficacy with alternating regimen as adjuvant
chemotherapy in stage 11 node-positive breast cancer:
results at 8 years (Pronacam 85)
R Chacon, L Romero Acunla, C Blajman, C Galvez, M Bruno, A Romero, G Chiessa, M Bader, R Schwan, C Albera,
MT Santarelli, F Sousa Martinez, J Nadal, M Viniegra and cooperating investigators
Cramer 1180 - (1426), Buenos Aires, Argentina
Summary A randomized trial to compare adjuvant treatment with an alternating regimen with conventional chemotherapy was performed. A
total of 589 node-positive patients were included and stratified according to number of positive nodes (N1-3 and N > 4) and menopausal
status. Premenopausal Ni-3 patients were randomized to cyclophosphamide, methotrexate and fluorouracil (CMF) or CMF/4'-epirubicin,
cyclophosphamide (EC), post-menopausal N1-3 patients tofluorouracil, 4 epirubicin, cyclophosphamide (FEC) orCMF/EC and pre- and post-
menopausal patients with N . 4 to fluorouracil, 4' epirubicin, cyclophosphamide, methotrexate, prednisone (FECMP) or CMF/EC. In
premenopausal patients, CMF was superiorto CMF/EC in terms of disease-free survival (DFS) (65% vs 45%, P= 0.0149) and survival (72.3%
vs 50.2%, P = 0.0220) whereas, for N 2 4 patients, differences between FECMP and CMF/EC did not achieve statistical significance (DFS
35% vs 26.2%; survival 50% vs 38.1%, P = NS). For post-menopausal patients, FEC was superior to CMF/EC in DFS (58.6% vs 36.8%,
P= 0.0215) and survival (66.2% vs 46%, P= 0.0155). In post-menopausal patients with N> 4, differences favouring CMF/EC were significant
in DFS (40.4% vs 22%, P = 0.0371) but not in survival (47.4% vs 32.2%, P = 0.1185). Alternating regimens did not offer better results in
premenopausal and post-menopausal N1-3 patients. Results regarding post-menopausal N > 4 women require further confirmation.
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Adjuvant chemotherapy reduces the risk of recurrence and death
in almost all prognostic groups of women with breast cancer
(EBCTCG, 1992). However, overall outcomes remain to be
improved, especially for node-positive patients. Attempts to
achieve better survival rates include the administration of new
agents, dose intensification and strategies to overcome or prevent
drug resistance. Goldie andColdman's hypothesis states that drug-
resistant clones could emerge from mutations produced before or
early during chemotherapy administration (Goldie and Coldman,
1979). This model emphasizes the importance ofapplying as many
effective drugs as possible in the shortest time interval. Alternating
non-cross-resistant regimens were tested in several clinical models
but, except for meclorethamine oncorin-procarbanin-prednisone-
adriamycin bleomycin rinblastine DTIC (MOPP-ABVD) vsMOPP
in advanced Hodgkin's disease (Bonadonna et al, 1986), their
superiority to standard treatment has not been demonstrated.
This trial was designed during the early 1980s to compare 4'
epirubicin standard regimens with the alternation of cyclophos-
phamide, methotrexate, fluorouracill4' epirubicin, cyclophos-
phamide (CMF/EC) in node-positive women with breast cancer.
Although the CMF regimen is considered to be standard treatment
for premenopausal patients with one to three positive axillary
nodes, outcomes for patients with more than four nodes, as well as
for post-menopausal women, are still suboptimal. Consequently,
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anthracycline-based schemes were used in these subsets. Likewise,
the combination of 4' epirubicin and cyclophosphamide has been
chosen because ofits efficacy in advanced disease and the theoret-
ical lack ofcomplete cross-resistance with the CMF regimen.
PATIENTS AND METHODS
Patients
Between July 1985 and July 1987, 589 consecutive women with
histologically confirmed axillary node-positive breast cancer were
included in this trial. Twenty-one patients were removed from the
study because of major violations of inclusion criteria, treatment
administration and lack of adequate follow-up data. Surgical
procedures included modified radical mastectomy, quadrantec-
tomy or tumorectomy (with uninvolved margins) plus axillary
node dissection.
Patients were excluded from the study if they had clinical
evidence of metastasis, were aged > 75 years or had a documented
history ofprevious cancer(except surgically treatedbasal cell carci-
nomaofthe skin orearly cervical carcinoma) orany systemic condi-
tion precluding properadministration ofchemotherapy. Histological
analyses of more than ten axillary lymph nodes were required.
Patients must have been included within 6 weeks from surgery.
Patients' characteristics (Tables 1 and 2) were homogeneously
distributed across treatment arms. During the inclusion period, the
technology for hormonal receptor assays was not available in
many centres throughout the country, and thus receptor status was
unknown for most patients (more than 70%). The high frequency
of T2 tumours (80%) and patients undergoing mastectomy (70%)
is also noteworthy.
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Table 1 Premenopausal patients' characteristics in relation to number of
positive nodes (1-3 or .4) and treatment regimens (CMF, CMF/EC or
FECMP)
1-3 .4
CMF CMF/EC CMF/EC FECMP
n (Randomized) 61 58 67 64
Removed (%) 1 (1.6) 2 (3.4) 3 (4.4) 3 (4.7)
n 60 56 64 61
Age (years) 40 42 42 42
(Range) (24-53) (23-52) (29-54) (26-52)
Type of surgery
Conservative 19 16 22 15
Mastectomy 41 40 42 46
Pathological tumour size
0-2 cm 13 25 15 12
2-5 cm 46 31 48 45
Not specified 1 0 1 4
Histological type (n)
Invasive ductal carcinoma 47 49 53 53
Invasive lobular carcinoma 8 3 9 7
Other 5 4 2 1
Table 2 Post-menopausal patients' characteristics in relation to number of
positive nodes (1-3 or .4) and treatment regimens (FEC, CMF/EC or
FECMP)
1-3 .4
FEC CMF/EC CMF/EC FECMP
n (Randomized) 87 78 84 90
Removed (%) 2 (2.2) 5 (6.4) 2 (2.3) 3 (3.3)
n 85 73 82 87
Age (years) 58 57 58.5 60
(Range) (45-72) (43-70) (42-70) (44-71)
Type of surgery
Conservative 32 21 18 21
Mastectomy 53 52 64 66
Pathological tumour size
0-2 cm 18 24 17 16
2-5 cm 67 49 64 70
Not specified 0 0 1 1
Histological type (n)
Invasive ductal carcinoma 77 59 73 69
Invasive lobular carcinoma 3 6 5 11
Other 5 8 4 7
Treatment regimens
Patients were randomly assigned to one oftwo regimens according
to their menopausal status and number of positive axillary nodes
(Figure 1). Post-menopausal status was defined by the absence of
menses during the last year. Treatment regimens are presented in
Table 3. Radiation therapy was administered to patients with
conservative surgery during or after chemotherapy.
No dose reduction was allowed. For patients with granulocyte
counts less than 1500 mm-3orplateletcounts less than 100 000 mm3,
chemotherapy was delayed for 1 or 2 weeks. If no haematological
recovery was observed at that time, the patient was removed
from study. Toxicity was recorded according to the WHO toxicity
criteria.
This protocol was approved by the human investigation
committees ofthe participating institutions.
Randomization
{
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Post-menopausal
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Figure 1 Randomization according to menopausal status and number of
positive lymph nodes
Statistical analysis
Disease-free survival (DFS; time of first adverse event) is defined
as the time to first occurrence ofprogressive disease or death from
any cause or to last follow-up, measured from time to entry to the
protocol. Survival is defined as the time to death from any cause or
to last follow-up, measured from time to entry to the protocol.
Differences in the distribution of patients' characteristics across
menopausal status were assessed using the exact test for contin-
gency tables. Disease-free survival and survival distribution were
estimated using the product limit method of Kaplan and Meier
(Kaplan andMeier, 1958). The statistical significance ofdifferences
observed in the distribution oftime to events was assessed using the
log-rank test (Peto et al, 1977). All P-values reported are two sided.
RESULTS
Disease-free survival and survival (Table 5)
Premenopausalpatients
Comparison between CMF and CMF/EC in patients with 1-3
positive nodes disclosed statistically significant differences in
DFS, in favour of CMF (log-rank test P = 0.015), with estimated
8-years DFS being 65% with CMF (95% CI 51-76%) vs 45%
(95% CI 32-58%) with CMF/EC. These differences were also
apparent for survival (P = 0.0220), with estimated 8-year survival
of 72.3% (95% CI 59-82%) vs 50.2% (36-66%) with CMF and
CMF/EC respectively. Figure 2A and B discloses survival curves
for both treatment arms. A median DFS of49 months for patients
in the CMF/EC arm was observed, whereas the median for CMF
patients has not yet been reached.
On the other hand, in patients with more than four positive
lymph nodes, CMF/EC has not produced better outcomes than
FECMP neither in DFS (log-rank test P = 0.3160) with estimated
8-year DFS of 26.2% (95% CI 14-40%) with CMF/EC and 35%
with FECMP (95% CI 21-49%) (Figure 2C) nor in survival (P =
0.2879) with estimated 8-year survival of38.1% (95% CI24-52%)
vs 50% (95% CI 36-62.5%) (Figure 2D). This lack of difference
persisted even when data were analysed for different positive node
strata (4-7 and > 8) (data not shown). Median DFS and survival in
patients treated with CMF/EC were shorter than those with
FECMP (60 and 83 months vs 77 and 96 months respectively).
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Table 3 Treatment regimens
Treatment CMFa CMF/ECb FECMPa FECa
Cyclophosphamide 600 mg m-2 Dl 600 mg m-2 Dl and 21 400 mg m-2 Dl 500 mg m-2 Dl
Methotrexate 40 mg m-2 Dl 40 mg m-2 Dl 30 mg m-2 Dl
Fluorouracil 600 mg m-2 Dl 600 mg m-2 Dl 400 mg m-2 Dl 500 mg m-2 Dl
4' Epirubicin - 60 mg m-2 D21 60 mg m-2 Dl 60 mg m-2 Dl
Prednisone - 40 mg m-2 &1 Dl to 5
aCMF, FECMP and FEC were administered every 21 days for six cycles. bCMF/EC was administered every 42 days for threecycles. D, day.
Table 4A Relative dose intensity for treatment regimens
Treatment CMF CMF/EC FECMP FEC
Cyclophosphamide 1 1 0.66 0.83
Methotrexate 1 0.5 0.75 0
Fluorouracil 1 0.5 0.66 0.83
4' Epirubicin 0 0.5 1 1
Prednisone 0 0 1 0
Table 4B Received dose intensity (mg per week)
Premenopausal Post-menopausal
N1-3 N24 N1-3 N24
Treatment CMF CMF/EC CMF/EC FECMP FEC CMF/EC CMF/EC FECMP
Cyclophosphamide 215.6 213.0 216.9 137.1 168.5 209.3 204.5 141.2
Methotrexate 14.4 7.1 7.2 10.3 - 7.0 6.8 10.6
Fluorouracil 215.6 106.0 108.4 137.1 168.5 104.6 102.3 141.2
4' Epirubicin - 10.6 10.8 20.6 20.2 10.5 10.2 21.2
Prednisone - - - 68.6 - - - 70.6
Post-menopausalpatients
In the subset with one to three positive nodes, patients randomized
to FEC did better than those in the CMF/EC arm (log-rank test for
DFS P = 0.0215), achieving a better estimated 8-year DFS -
58.6% for FEC (95% CI 47-69%) vs 36.8% for the alternating
scheme (95% CI 25-49%) (Table 5). Median DFS was 71 months
for CMF/EC. Median DFS has not been reached for patients
receiving FEC (Figure 3A). Differences in survival were also
significant (P = 0.0155), with estimated 8-year survival of 66.2%
(95% CI 54-76%) for FEC vs 46% (95% CI 33-58%) CMF/EC;
and the median survival for the FEC group was 25 months longer
than that for the CMF/EC group (116 vs 91 months) (Figure 3B).
Regarding patients with more than four lymph nodes, unex-
pected differences favouring the alternating chemotherapy group
were observed in DFS (P = 0.0371). Estimated 8-year DFS was
40.4% (95% CI 29-51%) with CMF/EC vs 22% (95% CI
13-32%) for FECMP; whereas survival figures have reached no
statistical significance (P = 0.1185), with estimated 8-year survival
of 47.4% (95% CI 36-58%) vs 32.2% (95% CI 22-43%) respec-
tively (Figure 3C and D). These results are not related to distribu-
tion of prognostic factors, such as number of positive nodes or
tumour size, as these variables were homogeneously distributed
across treatment arms.
Major sites of first relapse of disease were bone (18.2-31%),
skin (9.3-16.7%), liver(8.1-17.6%) andlung (5-16.3%) as well as
multiple metastatic involvement (15-33.1%). Multiple metastatic
involvement as the first manifestation of recurrence was more
frequently observed in premenopausal than in post-menopausal
patients (24.3% vs 16.7%). No other differences were found when
the pattern of relapse was analysed in relation to menopausal
status, nodal groups and chemotherapy regimens.
Toxicity
Information abouttoxicity is shown in Table 6. No patientrequired
hospitalization for toxic complications. No platelet or red cell
transfusions were administered. The most frequently reported
side-effects were emesis and alopecia. The percentage of courses
complicated with grade 3-4 emesis was slightly higher in the
anthracycline-containing regimens. The alternating regimen was
not less toxic than FECMP orFEC as long as anthracycline-related
alopecia was considered (76.6% for CMF/EC vs 85.1% and 80%
for FEC and FECMP respectively, P = 0.3634). No case of clini-
cally overt congestive heart failure was observed.
Two treatment-related deaths were reported. The first patient
developed liver failure during CMF treatment, while the second
patient suffered sudden death during FEC chemotherapy. Twelve
further patients died without evidence of relapse months to years
after completing chemotherapy. Information about causes ofdeath
was obtainedfrom clinical reports as autopsy was notperformed in
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Figure 2 Survival curves for premenopausal patients. (A) Disease-free survival for patients with one to three positive lymph nodes. (B) Survival for patients for
one to three positive lymph nodes. (C) Disease-free survival for patients with four or more positive lymph nodes. (D) Survival for patients with four or more
positive lymph nodes
Table 5 Estimated 8-year DFS and survival for different treatment groups
Positive nodes n Regimen DFS (%) 95% Cl P Survival (%) 95% Cl P
Premenopausal 1-3 60 CMF 65 50.7-76 0.0149 72.3 58.8-82.1 0.0220
56 CMF/EC 45.1 31.6-57.8 50.2 35.6-65.6
.4 64 CMF/EC 26.2 14.1-40 0.3160 38.1 24.4-51.8 0.2879
61 FECMP 35 21.2-48.9 50 35.7-62.5
Post-menopausal 1-3 85 FEC 58.6 46.7-68.7 0.0215 66.2 54.2-75.8 0.0155
73 CMF/EC 36.8 24.9-48.7 46 32.9-57.8
.4 82 CMF/EC 40.4 29.3-51.3 0.0371 47.4 35.7-58.1 0.1185
87 FECMP 22 13.3-32.2 32.2 22-42.8
any case. Eightpatients died of coronary conditions, one ofstroke;
there was one case of community overwhelming sepsis, one fatal
gastrointestinal haemorrhage and one sudden death. No patient
with coronary disease received radiotherapy to the left breast.
Second tumours
Ten patients developed second neoplasms. In eight cases the site
was the opposite breast; three of them are still disease free. One
patient had diagnosis of ovarian cancer and another had lung
cancer. Both patients died of disseminated disease attributable to
second malignancy.
DISCUSSION
Goldie andColdman's (1979) hypothesis, which is challengedby this
study, emphasizes the possibility of overcoming drug resistance by
the administration ofnon-cross-resistant chemotherapeutic regimens.
This assumption was based on a mathematical model as well as on
experimental and early clinical observations regarding advanced
Hodgkin's disease and small-cell lung cancer (Evans et al, 1987).
Our results in patients with one to three positive axillary nodes
suggest that six full cycles of CMF in premenopausal or FEC
in post-menopausal women are superior to the administration
of CMF/EC regimen for both DFS and survival. One possible
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Figure 3 Survival curves for post-menopausal patients. (A) Disease-free survival for patients with one to three positive lymph nodes. (B) Survival for patients
for one to three positive lymph nodes. (C) Disease-free survival for patients with four or more positive lymph nodes. (D) Survival for patients with four or more
positive lymph nodes
Table 6 Toxicity among different treatment regimens
CMF CMF/EC FEC FECMP
WBCa
Grade 3 <1 <1 <1 <1
Grade4 0 0 0 <1
Plateletsa
Grade 3-4 0 0 0 0
Emesisa
Grade 3 8.3 9.2 14.8 11.3
Grade 4 0 <1 <1 <1
Alopeciab
Grade 2 14 26.6 6.1 13.8
Grade 3 8.3 50 79 66.2
Mucositisa
Grade3 <1 <1 <1 <1
Grade 4 <1 <1 0 0
Cardiac (treatment-related sudden death) 1
Non-tumoral death (no. of events)
Total 2 6 3 3
Treatment related 1 0 1 0
aPercentage of courses complicated with toxicity. bPercentage of patients presenting this complication. WBC, white blood cell count.
explanation for this outcome is that the importance of delivering
critical amounts of a drug in a given interval (dose intensity)
outweighs that of more erratic exposure to agents with different
mechanisms of action and resistance. Similar conclusions were
drawn by other groups in early and advanced breast cancer (Spittle
et al, 1987; Budzar et al, 1988; Falkson et al, 1991; Bonadonna et
al, 1995). Conversely, results from the ECOG (Tormey et al, 1992)
showed prolonged DFS in patients receiving alternating chemo-
hormonotherapy in the adjuvant setting, although the use of
hormonal manipulation obscures the interpretation ofdata.
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On the other hand, for patients with more than four positive
lymph nodes, results diverge depending on menopausal status.
For younger patients, a trend favouring FECMP did not reach
statistical significance. This effect could reflect the actual lack
ofdifference or type II error related to the low statistical power of
the sample.
Findings regarding the superiority of CMF/EC in post-
menopausal patients deserve separate consideration. Although
dose intensity seems to be one ofthe - if not the most - important
features of breast cancer regimens, the relative contribution of
each drug to the final outcome is still unknown. In respect to that
mentioned above, it is likely that FECMP does not fit the require-
ments of an adequate regimen for dose intensity purposes (see
Table 4). Noteworthy are the results reported by Peters et al (1994)
about the critical importance of 5-FU dose intensity. Furthermore,
differences in pre- and post-menopausal tumour biology may
account for the apparent superiority of a non-cross-resistant
regimen as they do for the lower benefit from chemotherapy
reported for older women (EBCTCG, 1992).
Recent reports have raised the concern of anthracycline-related
carcinogenesis. It is noteworthy that no case of treatment-related
leukaemia has been observed among these more than 500 women
with a median follow-up of8 years. Likewise no report ofcumula-
tive cardiomyopathy was registered, confirming the low frequency
of such a complication in the current adjuvant setting (Chacon
et al, 1992).
In summary, our results suggest that alternating regimens offer
no advantage or even can compromise critical end points in pre-
and post-menopausal women with one to three positive axillary
nodes and premenopausal patients with more than four nodes. The
benefits of CMF/EC in post-menopausal patients with more than
four positive nodes require further confirmation.
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